Management of brain metastases according to molecular subtypes
R Soffietti, M Ahluwalia, N Lin, R Rudà - Nature Reviews Neurology, 2020 - nature.com
The incidence of brain metastases has markedly increased in the past 20 years owing to
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …
progress in the treatment of malignant solid tumours, earlier diagnosis by MRI and an …
Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data
EJ Lehrer, J Peterson, PD Brown, JP Sheehan… - Radiotherapy and …, 2019 - Elsevier
Background and purpose While the combination of stereotactic radiosurgery (SRS) and
immune checkpoint inhibitors (ICI) is becoming more widely used in the treatment of brain …
immune checkpoint inhibitors (ICI) is becoming more widely used in the treatment of brain …
Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression
N Galldiks, M Kocher, G Ceccon, JM Werner… - Neuro …, 2020 - academic.oup.com
The advent of immunotherapy using immune checkpoint inhibitors (ICIs) and targeted
therapy (TT) has dramatically improved the prognosis of various cancer types. However …
therapy (TT) has dramatically improved the prognosis of various cancer types. However …
Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non–small cell lung cancer to the brain: a matched cohort study
MJ Shepard, Z Xu, J Donahue, TJE Muttikkal… - Journal of …, 2019 - thejns.org
OBJECTIVE Immune checkpoint inhibitors (ICIs) improve survival in patients with advanced
non–small cell lung cancer (NSCLC). Clinical trials examining the efficacy of ICIs in patients …
non–small cell lung cancer (NSCLC). Clinical trials examining the efficacy of ICIs in patients …
The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis
Background The response of brain metastases (BM) treated with stereotactic radiosurgery
(SRS) and immune checkpoint inhibitors (ICIs; programmed cell death 1 and its ligand) is of …
(SRS) and immune checkpoint inhibitors (ICIs; programmed cell death 1 and its ligand) is of …
[HTML][HTML] Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity
G Minniti, D Anzellini, C Reverberi… - … for immunotherapy of …, 2019 - Springer
Purpose To investigate the efficacy and safety of concurrent stereotactic radiosurgery (SRS)
and ipilimumab or nivolumab in patients with untreated melanoma brain metastases …
and ipilimumab or nivolumab in patients with untreated melanoma brain metastases …
Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity
Introduction There is evidence that the combination of ipilimumab and stereotactic
radiosurgery (SRS) for brain metastases improves outcomes. We investigated clinical …
radiosurgery (SRS) for brain metastases improves outcomes. We investigated clinical …
Imaging-defined necrosis after treatment with single-fraction stereotactic radiosurgery and immune checkpoint inhibitors and its potential association with improved …
OBJECTIVE Immune checkpoint inhibitors (ICIs) and stereotactic radiosurgery (SRS) are
commonly utilized in the management of brain metastases. Treatment-related imaging …
commonly utilized in the management of brain metastases. Treatment-related imaging …
[HTML][HTML] Immunotherapy in NSCLC patients with brain metastases
S Buriolla, G Pelizzari, C Corvaja, M Alberti… - International journal of …, 2022 - mdpi.com
Approximately 40% of unselected non-small cell lung cancer (NSCLC) patients develop
brain metastases (BMs) during their disease, with considerable morbidity and mortality. The …
brain metastases (BMs) during their disease, with considerable morbidity and mortality. The …
[HTML][HTML] Neoadjuvant immunotherapy in gastrointestinal cancers–The new standard of care?
B Petricevic, J Kabiljo, R Zirnbauer, H Walczak… - Seminars in cancer …, 2022 - Elsevier
The development of immune checkpoint inhibitors (ICI) offers novel treatment possibilities for
solid cancers, with the crucial benefit of providing higher cure rates. These agents have …
solid cancers, with the crucial benefit of providing higher cure rates. These agents have …